Six years of adjuvant imatinib versus three improved GIST disease-free survival in IMADGIST

A systematic review with an exploratory network meta-analysis, published in BMC Gastroenterology, examined adjuvant imatinib given for longer than three years to patients with high-risk gastrointestinal stromal tumors (GIST). The authors searched PubMed, Embase and the Cochrane Library through April 19, 2026. Twenty-two reports representing 13 independent studies were included: four randomized trials, two prospective single-arm trials and seven cohort studies biomedcentral.comBMC Gastroenterologybiomedcentral.comOpen source ↗.

Three years of adjuvant imatinib is the established standard for high-risk GIST. Recurrence after treatment cessation, however, raises the question of whether longer courses are justified, and the review focused on treatment beyond 3 years and on factors relevant to patient selection.

Recurrence-related outcomes

In the IMADGIST trial, 6 years of imatinib improved disease-free survival (DFS) compared with 3 years: hazard ratio (HR) 0.40, 95% confidence interval (CI) 0.20–0.69, P = 0.0008.

The exploratory frequentist network meta-analysis compared placebo/observation with 1-, 3- and 6-year adjuvant imatinib strategies. In the three-trial network, the 6-year strategy had the highest P-score, 0.9994, and an indirect estimated HR of 0.09 (95% CI, 0.04–0.21) versus placebo/observation biomedcentral.comBMC Gastroenterologybiomedcentral.comOpen source ↗.

The authors note that the linear network, differences in trial populations and distinct randomization time points limit the interpretation of these indirect rankings.

Overall survival and patient selection

Comparison of 3 versus 1 year of imatinib showed a long-term overall survival (OS) benefit. An additional OS benefit from treatment beyond 3 years has not been established.

Molecular characteristics, recurrence risk and tolerability were identified as relevant to individualized treatment decisions. In PERSIST-5, 51% of participants completed the planned 5-year course biomedcentral.comBMC Gastroenterologybiomedcentral.comOpen source ↗.

The authors propose a Personalized Triangle Framework that integrates molecular sensitivity, recurrence risk and tolerability. They describe it as a conceptual aid rather than a validated treatment-selection algorithm.

The authors conclude that extending adjuvant imatinib beyond 3 years improves recurrence-related outcomes in selected high-risk GIST patients, while the optimal duration and the long-term OS effects remain uncertain.